Solid Organ Transplant Boosts Burkitt's Lymphoma Risk

According to researchers at the National Cancer Institute in Bethesda, Maryland, people receiving solid organ transplants are at a significantly higher risk of developing one of the most aggressive cancers ever documented, the non-Hodgkin's lymphoma known as Burkitt's lymphoma.

Researchers reviewed the incidence of Burkitt's in 203,557 solid organ recipients listed in the U.S. Transplant Cancer Match Study between 1987 to 2009. They determined that U.S. transplant recipients are 23 times more likely to develop Burkitt's than members of the general population.

When does Burkitt's develop?

Burkitt's tended to peak in these patients between three and eight years following transplant, which differs substantially from the peak incidences of viral malignancies like Kaposi's sarcoma, which peak a year after transplant.

Their findings have been published in the American Journal of Hematology, where they wrote:

"This longer latency suggests that progression to BL occurs after chronic immunosuppression and chronic EBV [Epstein-Barr virus] infection. Alternatively, the lower incidence of BL in the first few years after transplantation may reflect the negative impact of intense immunosuppression on progression to BL during that period."

Who is at risk?

Burkitt's incidence was much higher in younger patients, specifically among those who received the transplant before they reached 18, compared with those who received the transplant after they were 35. It was also higher in patients receiving liver and heart transplants, but lower in those receiving kidney transplants.

Source: American Journal of Hematology

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap